---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-225055"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2026-05-15T10:02:44+00:00"
generated_at: "2026-05-15T10:22:37.219882+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma reports Q1 revenue $22.7M, neffy net product revenue $17.5M

## Summary
- Net loss $60.6M ($0.61/share); cash $201M; expects to fund to cash-flow break-even.
- CVS Caremark formulary proposal in final stages; target July 1, 2026; gross-to-net target ~50%.
- Sales force expanded to 148 reps; SG&A $72.2M includes DTC marketing investment.
- Health Canada approved neffy on April 15; EU 1 mg dose approved for children 4+ years.
- Phase 2b CSU trial interim population fully enrolled; data expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-225055
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2026-05-15T10:02:44+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/0001193125-26-225055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/spry-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-225055
- JSON: https://secwatch.observer/filing/0001193125-26-225055.json
- Plain text: https://secwatch.observer/filing/0001193125-26-225055.txt

## Key facts
- Earnings Releases
  ARS Pharmaceuticals, Inc. reported first quarter of 2026 results: revenue $22.7 million, net income ($60.6 million), EPS ($0.61) per share basic and diluted.
  - Period: first quarter of 2026
  - Revenue: $22.7 million
  - Net income: ($60.6 million)
  - EPS: ($0.61) per share basic and diluted
  - Result: reported results
  source text: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 total revenue of $22.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312526225055/0001193125-26-225055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.